Schrödinger, Inc.
NASDAQ:SDGRMedical - Healthcare Information Services
+$0.00 today
- Market cap
- $1.79B
- Beta
- 1.64
- P/E (TTM)
- -11.1
- EPS (TTM)
- -$1.40
Volume 1.18M
Average 1.35M
SDGR Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Schrödinger, Inc.NASDAQ: SDGR
Net Receivables · Q3 FY2026 · quarter ended Sep 2026
Net receivables falls 15.7% from a year ago
Net receivables stood at $48.36M at the end of Q3 FY2026, down 15.7% from a year earlier and up 17.6% from the prior quarter. Over 3 fiscal years it compounded at +14.7% a year.
Context
- Net receivables amounted to 7.9% of total assets at the end of Q3 FY2026, down 0.9 pp from a year earlier.
- Net receivables increased in 2 of the last 3 fiscal years.
What to watch
Whether net receivables keeps falling in the next quarterly balance sheet after a -15.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 104.39M USD
- Year-over-year change
- -59.1%
- 4-year CAGR
- +26.7%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 104.39M | -59.1% |
| FY2024 | 2024-12-31 | 255.33M | +186.5% |
| FY2023 | 2023-12-31 | 89.12M | +29.0% |
| FY2022 | 2022-12-31 | 69.09M | +70.4% |
| FY2021 | 2021-12-31 | 40.55M | — |
Net Receivables vs competitors
How SDGR compares with its peers on the latest reported figures
- Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -15.7% is the 4th highest of 6, against a peer median of +2.3%.
- Net receivables amounts to 7.9% of total assets for SDGR, versus a peer median of 5.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jul 2026 | $565.65M USD | +19.7% | +18.6% | 6.2% | |
| Mar 2026 | $107.61M USD | +2.3% | +9.4% | 7.2% | |
| Sep 2026 | $67.28M USD | -57.8% | +14.0% | 4.5% | |
| Sep 2026 | $48.36M USD | -15.7% | +14.7% | 7.9% | |
| Feb 2026 | $18.17M USD | +10.2% | +2.0% | 12.4% | |
HYFTMindWalk Holdings Corp. | Jan 2026 | CA$3.03M CAD | -37.7% | +12.1% | 13.1% |
| Jun 2026 | $0 USD | — | — | 0.0% | |
GENBGenerate Biomedicines, Inc. | Mar 2026 | $0 USD | — | — | 0.0% |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding SDGR) | — | +2.3% | +12.1% | 5.4% | |
Competitors are the stored peer set for SDGR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 120.27M | 90.47M | 155.32M | 147.33M | 230.52M |
| Short-term Investments | 456.21M | 360.61M | 307.69M | 204.8M | 164.95M |
| Net Receivables | 40.55M | 69.09M | 89.12M | 255.33M | 104.39M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 3M | 5.24M | 5.75M | 15.33M | 6.87M |
| Total Current Assets | 625.06M | 533.99M | 567.8M | 634.99M | 519.27M |
| Property, Plant & Equipment (Net) | 85.41M | 120.23M | 141.1M | 136.08M | 122.19M |
| Goodwill | 0 | 4.79M | 4.79M | 4.79M | 4.79M |
| Intangible Assets | 0 | 587K | 0 | 0 | 0 |
| Long-term Investments | 43.17M | 25.68M | 83.25M | 43.21M | 73.65M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 2.85M | 3.31M | 6.01M | 4.16M | 6.27M |
| Total Non-current Assets | 131.43M | 154.6M | 235.16M | 188.23M | 206.9M |
| Total Assets | 756.49M | 688.59M | 802.96M | 823.23M | 726.16M |
| Account Payables | 8.08M | 9.47M | 16.82M | 10.67M | 11.45M |
| Short-term Debt | 0 | 0 | 0 | 0 | 16.41M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 55.37M | 57.93M | 56.23M | 111.94M | 112.85M |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 48.42M |
| Total Current Liabilities | 91.21M | 108.8M | 133.67M | 191.75M | 189.14M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 30.06M | 25.6M | 9.04M | 108.81M | 78.88M |
| Other Non-current Liabilities | 300K | 800K | 667K | 146K | 1.28M |
| Total Non-current Liabilities | 108.19M | 131.88M | 120.72M | 210.03M | 172.97M |
| Total Liabilities | 199.4M | 240.68M | 254.4M | 401.78M | 362.11M |
| Common Stock | 710K | 714K | 722K | 729K | 645K |
| Retained Earnings | (229.95M) | (379.14M) | (338.42M) | (525.54M) | (628.81M) |
| Accumulated OCI | (651K) | (2.38M) | 281K | 220K | 107K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 14K | 11K | 0 | 0 | 0 |
| Total Equity | 557.09M | 447.91M | 548.56M | 421.45M | 364.05M |
| Total Debt | 79.87M | 116.49M | 127.88M | 117.83M | 109.23M |
| Net Debt | (40.4M) | 26.02M | (27.43M) | (29.5M) | (121.29M) |
Schrödinger, Inc.
NASDAQ:SDGR
Intrinsic Alpha fair value
Locked
Current Price
$27.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.